Pharsight

Piqray patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(5 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)

Piqray is owned by Novartis.

Piqray contains Alpelisib.

Piqray has a total of 2 drug patents out of which 0 drug patents have expired.

Piqray was authorised for market use on 24 May, 2019.

Piqray is available in tablet;oral dosage forms.

Piqray can be used as in combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer.

Drug patent challenges can be filed against Piqray from 25 May, 2023.

The generics of Piqray are possible to be released after 29 April, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
New Indication(I-937) Jan 18, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

PIQRAY family patents

Family Patents